{
  "docId": "019de073-7b6a-72bb-8d98-812d56d63617",
  "docSlug": "f8b2787992eb3375620f74057447d0c9",
  "documentTitle": "Aravive | Investor Presentation Deck | 39 slides",
  "authorId": "aravive",
  "authorName": "Aravive",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 39,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 11,
  "notes": "The slide uses a process flow diagram to show the Phase 1b study arms.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7b6a-72bb-8d98-812d56d63617/13",
  "deckHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617",
  "deckJsonHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617.json",
  "deckAnchorHref": "/decks/019de073-7b6a-72bb-8d98-812d56d63617#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.5,
        "y": 0.45
      },
      "kind": "diagram",
      "text": "Flowchart showing Batiraxcept dosing arms with PAC and PLD combinations.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2624d227-4e60-45fb-9f26-ce85738bbacb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.6,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "Phase 1a single ascending dose and repeat dose study in healthy volunteers: 43 subjects participated; 42 dosed; well-tolerated; no SAEs; no ADA; 10 mg/kg (IV) suppressed serum GAS6 levels for 2 weeks.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "587711d1-fa49-4f70-a973-cfc461b3e689",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "list",
      "text": "Phase 1b ascending dose study in Platinum-Resistant Ovarian Cancer (PROC): 53 patients; well-tolerated; no dose-limiting toxicities; no discontinuations; no ADA; infusion-related reactions managed; exposure-response at 10 mg/kg.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e850efb4-54b9-40b2-802d-c6035f835459",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.55,
        "y": 0.8
      },
      "kind": "paragraph",
      "text": "Batiraxcept IV q14 days; Pegylated liposomal doxorubicin (PLD) 40 mg/m2 d1 of 28-day cycle; Paclitaxel (PAC) 80 mg/m2 day 1, day 8, day 15 of 28-day cycle; Maintenance dosing on batiraxcept monotherapy",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81595fc9-f72e-478a-bcbe-15ec42c53ebf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Summary of Phase 1a Healthy Volunteer and 1b PROC Studies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32066b7b-ff8a-4b42-95d8-3f49848ae6c5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "7290ba57-4fda-4992-9040-e331163f8556",
      "evidence": "list/bullet: Phase 1b ascending dose study in Platinum-Resistant Ovarian Cancer (PROC): 53 patients; well-tolerated; no dose-limiting toxicities; no discontinuations; no ADA; infusion-related reactions managed; exposure-",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 15,
      "from": 12,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "ca889fd8-550d-4690-bdfd-ec18eba75312",
      "evidence": "The document presents promising results for Batiraxcept in PROC and highlights its potential for expansion into other indications",
      "position": 1,
      "objective": "Can Batiraxcept provide a quick win in PROC and a big bet for future growth?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}